Who are Oragenics, Inc.'s main suppliers?

Oragenics, Inc. (OGEN) key suppliers include: INSURANCE-PREMIUM-FINANCING, RESEARCH-AND-DEVELOPMENT-VENDORS, SIGYN-THERAPEUTICS-INC. View the full supplier network at chainsifter.com/chain/OGEN.

Who are Oragenics, Inc.'s major customers?

Oragenics, Inc. (OGEN) key customers include: Sigyn Therapeutics, Inc., Sigyn Therapeutics, Inc.. View the full customer network at chainsifter.com/chain/OGEN.

What sector is Oragenics, Inc. in?

Oragenics, Inc. (OGEN) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Oragenics, Inc. Supplier List (OGEN): 3 Verified Suppliers

3Suppliers

2Customers

3Debt Items

1Related Chains

Source-Backed Evidence Depth

Oragenics, Inc. (OGEN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

9Total relationships

2Distinct source URLs

9High confidence

0.891Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Oragenics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
INSURANCE-PREMIUM-FINANCING	INSURANCE-PREMIUM-FINANCING	92%	Insurance premium financing of $506,190, due in monthly installments of $58,314, which includes principal and annual interest at 8.75% through April 2026
RESEARCH-AND-DEVELOPMENT-VENDORS	RESEARCH-AND-DEVELOPMENT-VENDORS	90%	These liabilities consist primarily of account payables to research and development vendors, payroll and benefits accruals, professional service fees, and other general corporate obligations
SIGYN-THERAPEUTICS-INC	SIGYN-THERAPEUTICS-INC	90%	Oragenics, Inc. has signed a Letter of Intent with Sigyn Therapeutics, Inc. to license CardioDialysis™, an extracorporeal blood purification technology

Oragenics, Inc. Customers

Ticker	Name	Confidence	Evidence
SIGY	Sigyn Therapeutics, Inc.	85%	we seek to enhance shareholder value by evaluating business development opportunities both within and complementary to our current business, as well as opportunities that may be new and separate from…
SIGY	Sigyn Therapeutics, Inc.	85%	Reciprocal relationship from SIGY graph: Reciprocal relationship from OGEN graph: Reciprocal relationship from SIGY graph: Reciprocal relationship from OGEN graph: Reciprocal relationship from SIGY g…

Oragenics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
OGEN-DEBT	Debt stack $56,134	90%	Market cache reports total debt of $56,134.
OGEN-DEBT-11493	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2015-12-31.
OGEN-DEBT-11492	Warrants outstanding: 13800000	90%	xbrl warrant detail from xbrl 2021-12-31.

Oragenics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Oragenics, Inc..

Oragenics, Inc. Ownership

Holder	Name	Confidence	Evidence
OGEN-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC	Geode Capital Management, LLC	90%	13F overlay lists Geode Capital Management, LLC as top holder; 10 tracked holders.

Oragenics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
SIGY	Sigyn Therapeutics, Inc.	45.90	1	['customer']

Oragenics, Inc. Supply Chain